Left Ventricular Assist Device
Q&A: New technology may become second mechanical heart pump available in US
Left ventricular assist devices, which are mechanical heart pumps, are an important treatment for patients with advanced heart failure.
FDA OKs updated label allowing aspirin to be dropped after LVAD implant
Abbott announced the FDA approved elimination of aspirin as part of routine management from the label of its fully magnetically levitated left ventricular assist device.
Q&A: Stanford Children’s heart transplant patients ‘not just surviving but thriving’
Stanford Medicine Children’s Health this year celebrated 50 years of pediatric heart transplants and more than 35 years of pediatric lung transplants, according to a press release.
FDA designates recall of display used with LV assist system as class I
Abbott issued a recall and correction for its left ventricular assist system monitor due to atypical behavior of the device screen that may cause unintentional pump stop.
Recall of LVAD implant kit designated class I; two deaths reported
Abbott/Thoratec Corp. announced the recall of its left ventricular assist device implant kit due to complaints of blood leakage or air entering the seal interface between the LVAD inflow cannula and the apical cuff.
Top in cardiology: E-cigarettes linked to heart failure; FDA labels LVAD recall as class I
People who used e-cigarettes had a 19% elevated risk for heart failure compared with never users, according to a study of 175,667 participants that was presented at the American College of Cardiology Scientific Session.
LVAD obstruction linked to 14 deaths; FDA designates recall as class I
Abbott/Thoratec Corp. issued a recall of two of its left ventricular assist devices due to risk for obstruction from the long-term buildup of biological material during use.
Q&A: Considerations for sustaining advancement of durable mechanical circulatory support
Since the implant of the first left ventricular assist device in 1994, the HF community observed significant technological innovation in durable mechanical circulatory support.
FDA designates recall of LVAD communication system as class I
Abbott announced it is recalling its left ventricular assist device communication system due to risk for unexpected pump stop or start.
Procedure rates for women, Black men with HFrEF disparate vs. white men
Despite narrowing sex and racial procedural disparities in HF treatment, gaps persist, with lower rates of left ventricular assist device use and heart transplant among women and Black men vs. their white and male counterparts, data show.